Medical Advocates
ART/HAART
  Treatment Interruption
 Journal Citations

 General Reports/Studies
Retrospective Studies
 Viral Dynamics
 Resistance
 Adverse Events



 
Treament Interruption Main Page Main New/Newsworthy Home Page      
Last Update:  October 07, 2006
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports/Studies
     
 
Structured treatment interruptions: after SMART.
Sledge M.
 BETA. 2006 Summer;18(4):30-6.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
FULL TEXT PDF ARTICLE
 Structured treatment interruptions–new findings.
 Benson CA
 Top HIV Med. 2006 Aug-Sep;14(3):107-11
 Abstract
 
Evidence That Intermittent Structured Treatment Interruption, but Not Immunization with ALVAC-
HIV vCP1452,Promotes Host Control of HIV Replication: The Results of AIDS Clinical Trials Group
5068.
Jacobson JM, Pat Bucy R, Spritzler J, et al
 J Infect Dis. 2006 Sep 1;194(5):623-32.
 Abstract
 
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with
HIV-1: results of the Staccato randomised trial.
 Ananworanich J, Gayet-Ageron A, Le Braz M, et al
 Lancet. 2006 Aug 5;368(9534):459-65.
 Abstract
 
Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.
Pai N, Lawrence J, Reingold A, Tulsky J. 
Cochrane Database Syst Rev. 2006 Jul 19;
 Abstract
 
Treatment interruptions in HIV-infected subjects.
Bongiovanni M, Casana M, Tincati C, d’Arminio Monforte A.  
J Antimicrob Chemother. 2006 Jul 1;
Abstract
 
Treatment Interruption in HIV Therapy: a SMART Strategy?
Julg B, Goebel FD.  
Infection. 2006 Jun;34(3):186-8.
Abstract
 
Structured Treatment Interruptions in Primary HIV-1 Infection: The ANRS 100 PRIMSTOP Trial.
Hoen B, Fournier I, Lacabaratz C,  et al
J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):307-316.
 Abstract
 
Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in
HIV-infected patients: a prospective study.
Mussini C, Pinti M, Bugarini R, Borghi V 
AIDS. 2005 Oct 14;19(15):1627-1633.
 Abstract

FULL-TEXT ARTICLE
 Randomized, Controlled Trial of Therapy Interruption in Chronic HIV-1 Infection
Papasavvas E,  Kostman JR,  Mounzer K,  et al
PLOS Medicine Vol2 Issue 9 Sep 2005
 Paper

Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA
and > 400 CD4(+) cells/microl? Impact on immunovirological parameters.
 Pellegrin I, Thiebaut R, Blanco P, et al 
J Med Virol. 2005 Aug 24;77(2):164-172
 Abstract
 
Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly
active antiretroviral therapy is resumed after treatment interruption.
 Barreiro P, de Mendoza C, Gonzalez-Lahoz J, Soriano V.
Clin Infect Dis. 2005 Sep 15;41(6):897-900
Abstract
 
Structured Intermittent Therapy with Seven-Day Cycles of HAART for Chronic HIV Infection:
A Pilot Study in Sao Paulo, Brazil.
Casseb J, Da Silva Duarte AJ.
AIDS Patient Care STDS. 2005 Jul;19(7):425-8.
 Abstract
 
Highly Active Antiretroviral Therapy (HAART) Retreatment in Patients on CD4-Guided
Therapy Achieved Similar Virologic Suppression Compared With Patients on
Continuous HAART: The HIV Netherlands Australia Thailand Research Collaboration
001.4 Study.
 Ananworanich J, Siangphoe U, Hill A, et al 
J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):523-529.
 Abstract
 
Treatment interruption in 30 HIV-infected patients with successful viral suppression under highly
active antiretroviral treatment
Pavie J, Porcher R, Fournier S, et al 
Presse Med. 2005 Jun 4;34(10 Suppl):1S8-13.
Abstract
 
Interruption of antiretroviral therapy in chronically HIV-infected patients.
 Amador C, Pasquau F, Ena J, Benito C, et al 
Med Clin (Barc). 2005 Jun 11;125(2):41-5
 Abstract
 
A Prospective, Randomized Trial of Structured Treatment Interruption for Patients with
Chronic HIVType 1 Infection.
 Cardiello PG, Hassink E, Ananworanich J, et al   
Clin Infect Dis. 2005 Feb 15;40(4):594-600.
Abstract
 
Interruption of Highly Active Antiretroviral Therapy in HIV Clinical Practice:
Results From the Italian Cohort of Antiretroviral-Naive Patients.
 Monforte AD, Cozzi-Lepri A, Phillips A, et al 
J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):407-416.
 Abstract
 
Prolonged treatment interruption in chronic HIV infection: a new strategy?
 Giuntini R, Martinelli C, Ambu S, et al
AIDS. 2005 Jan 28;19(2):209-11.
 Abstract
 
Extended antiretroviral treatment interruption in HIV-infected patients with long-term
suppression of plasma HIV RNA.
 Achenbach C, Till M, Palella F 
HIV Med. 2005 Jan;6(1):7-12.
 Abstract
 
FULL-TEXT ARTICLE
Randomized, Controlled Trial of Therapy Interruption in Chronic HIV-1 Infection.
Papasavvas E, Kostman JR, Mounzer K, et al
PLoS Med. 2004 Dec;1(3):e64.
Paper

Immunological markers after long-term treatment interruption in chronically HIV-1 infected
patients with CD4 cell count above 400 x 106 cells/l.
 Thiebaut R, Pellegrin I, Chene G, et al  
 AIDS. 2005 Jan 3;19(1):53-61.
Abstract
 
CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good
response tohighly active antiretroviral therapy.
 Boschi A, Tinelli C, Ortolani P, et al 
AIDS. 2004 Dec 3;18(18):2381-9.
 Abstract
 
Antiretroviral drug treatment interruption in human immunodeficiency virus-infected
adults: Clinical and pathogenetic implications for the central nervous system.
 Price RW, Deeks SG. 
J Neurovirol. 2004;10 Suppl 1:44-51
 
Predictors of sustained response to therapy resumption after treatment interruption in HIV-
infected patients failing antiretroviral therapy.
 Gianotti N, Soria A, Galli L, et al.
 Med Virol. 2004 Feb;72(2):181-186.
 Abstract
 
Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of
highly active antiretroviral therapy initiated at acute infection combined with structured treatment
interruptions and immune-based therapies.
 Lafeuillade A, Poggi C, Hittinger G, et al 
J Infect Dis. 2003 Nov 15;188(10):1426-32.
 Abstract
 
Role of Structured Treatment Interruption before a 5-Drug Salvage Antiretroviral Regimen: The
Retrogene Study.
Ruiz L, Ribera E, Bonjoch A, et al
 J Infect Dis. 2003 Oct 1;188(7):977-8
 Abstract
 
Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.
Lawrence J, Mayers DL, Hullsiek KH, et al  
N Engl J Med. 2003 Aug 28;349(9):837-46.
 Abstract
 
Long-Cycle Structured Intermittent versus Continuous Highly Active Antiretroviral Therapy for the
Treatment of Chronic Infection with Human Immunodeficiency Virus: Effects on Drug Toxicity and
on Immunologic and Virologic Parameters.
Dybul M, Nies-Kraske E, Daucher M, et al
J Infect Dis. 2003 Aug 1;188(3):388-96.
Abstract
 
Interruption of Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Therapy for 2 Months Has
No Effect on Levels of Human Immunodeficiency Virus Type 1 in Plasma of Patients Harboring
Viruses with Mutations Associated with Resistance to NNRTIs.
Wirden M, Simon A, Schneider L, et al.
J Clin Microbiol. 2003 Jun;41(6):2713-5.
Abstract

HIV RNA in plasma rebounds within days during structured treatment interruptions.
Fischer M, Hafner R, Schneider C, et al
 AIDS 2003 Jan 24;17(2):195-9
 Abstract

A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions:
a randomized study.
Garcia F, Plana M, Arnedo M, et al.
AIDS 2003 Jan 3;17(1):43-51
 Abstract

Planned interruptions of anti-HIV treatment.
Hirschel B.
Lancet Infect Dis 2001 Aug;1(1):53-9
 Abstract
 

  
Cytokine therapy or structured treatment interruptions in HIV infection: which is best?
Parienti JJ.
Expert Opin Pharmacother  2002 Jun;3(6):719-26  
Abstract
 
FULL-TEXT ARTICLE
 Short-cycle structured intermittent treatment of chronic HIV infection with highly active
antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters.
Dybul M, Chun TW, Yoder C, Hidalgo B, et al
Proc Natl Acad Sci U S A 2001 Dec 4;
 Paper
 
  FULL-TEXT ARTICLE
 Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.
Ortiz GM, Wellons M, Brancato J. et al
Proc Natl Acad Sci U S A 2001 Nov 6;98(23):13288-93
 Paper
Retrospective Studies
     
  Structured treatment interruptions as a potential alternative therapeutic regimen for HIV-
infected patients: a review of recent clinical data and future prospects.
 Lori F, Foli A, Lisziewicz J.
J Antimicrob Chemother 2002 Aug;50(2):155-60
 Abstract
Diagnostics/Monitoring
     
  Determinants of HIV drug resistance mutations in plasma virus after treatment interruption.
 Chilton D, Dervisevic S, Pillay D, et al
AIDS. 2005 Dec 2;19(18):2174-2175.
 Abstract
Viral Dynamics Studies
     
 
A WEEK-IN-REVIEW FEATURED REPORT
The Role of Hydroxyurea in Enhancing the Virologic Control Achieved through Structured
Treatment Interruption in Primary HIV Infection: Final Results from a Randomized Clinical
Trial (Pulse).
Bloch MT, Smith DE, Quan D, et al
J Acquir Immune Defic Syndr. 2006 May 8;
Abstract

Viral Evolution during Structured Treatment Interruptions in Chronically Human
Immunodeficiency Virus-Infected Individuals.
Martinez-Picado J, Frost SD, Izquierdo N, et al.
J Virol 2002 Dec 1;76(23):12344-12348
 Abstract

Virological and immunological effects of salvage therapy following treatment interruption  
and a shift in HIV-1resistance genotype.
 Izopet J, Souyris C, Sandres-Saune K, et al.
 J Med Virol 2002 Nov;68(3):305-10
 Abstract
 
Viral dynamics during structured treatment interruptions of chronic human immunodeficiency
virus  type 1 infection.
Frost SD, Martinez-Picado J, Ruiz L, et al.  
 J Virol 2002 Feb;76(3):968-79
 Abstract
 
FULL-TEXT ARTICLE
 Short-cycle structured intermittent treatment of chronic HIV infection with highly active
antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters.
Dybul M, Chun TW, Yoder C, Hidalgo B, et al
Proc Natl Acad Sci U S A 2001 Dec 4;
 Paper
 
The virological and immunological consequences of structured treatment interruptions in
chronic HIV-1 infection.
Garcia F, Plana M, Ortiz GM, et al.
AIDS 2001 Jun 15;15(9):F29-40
 Abstract
Resistance
     
 
Evolution of HIV resistance during treatment interruption in experienced patients and after restarting
a new therapy.
 Balduin M, Sierra S, Daumer MP, et al
J Clin Virol. 2005 Sep 24;
Abstract

Evolution of HIV resistance during treatment interruption in experienced patients and after restarting
a new therapy.
 Balduin M, Sierra S, Daumer MP, et al
 J Clin Virol. 2005 Sep 24
 Abstract
Adverse Events
     
 
FULL-TEXT PDF ARTICLE
 Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in
HIV-1 infection.
 Gisslen M, Rosengren L, Hagberg L, et al   
AIDS Res Ther. 2005 Aug 18;2(1):6
 Paper
 
Symptomatic HIV viraemia during a drug holiday: an argument against treatment
interruption?
 Freedman E, Dhaliwal K, Estcourt C, et al  
Int J STD AIDS. 2004 Aug;15(8):564-5.
Abstract

A Case of Multiorgan Failure Following Interruption of Antiretroviral Treatment.
 Crespo M, Paradineiro JC, Ribera E, et al 
Eur J Clin Microbiol Infect Dis. 2003 Dec 11
 Abstract

Recurring thrombocytopenia associated with structured treatment interruption in patients
with human immunodeficiency virus infection.
 Ananworanich J, Phanuphak N, Nuesch R, et al
Clin Infect Dis. 2003 Sep 1;37(5):723-5.
Abstract
 
Anti-retroviral treatment interruptions in HIV-infected adults: causes, clinical, immunological
and virological consequences
 Sommet A, Delpierre C, Cuzin L, et al.
Rev Med Interne. 2003 Jun;24(6):350-7.
Abstract

Treament Interruption Main Page Main New/Newsworthy Home Page      

 Treatment Interruption Journal Citations